Patents by Inventor Ronald A. Morena

Ronald A. Morena has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiolabeling method
    Patent number: 7608241
    Abstract: Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: October 27, 2009
    Assignee: Rit Oncology, LLC
    Inventors: Paul Chinn, Ronald A. Morena, Michael J. LaBarre, John E. Leonard
  • Radiolabeling method
    Publication number: 20050169838
    Abstract: Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.
    Type: Application
    Filed: January 12, 2005
    Publication date: August 4, 2005
    Applicant: Biogen Idec Inc.
    Inventors: Paul Chinn, Ronald Morena, Michael LaBarre, John Leonard
  • RADIOLABELING KIT AND BINDING ASSAY
    Publication number: 20020102208
    Abstract: Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.
    Type: Application
    Filed: March 1, 1999
    Publication date: August 1, 2002
    Inventors: PAUL CHINN, RONALD MORENA, MICHAEL LABARRE, JOHN E. LEONARD